Skip to content
10-K

Annual Report

Mineralys Therapeutics, Inc. MLYS

0001933414-26-000056

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 5, 2026 82.4M sh
Shares Diluted FY 2025 · Dec 31, 2025 67.66M sh
Shares Diluted FY 2025 · Dec 31, 2024 48.54M sh
Capex FY 2025 · Dec 31, 2025 $15K
Capex FY 2025 · Dec 31, 2024 $96K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$142.42M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$166.31M
Cash And Equivalents FY 2025 · Dec 31, 2025 $172.92M
Cash And Equivalents FY 2025 · Dec 31, 2024 $114.09M
Stockholders Equity FY 2025 · Dec 31, 2025 $646.69M
Stockholders Equity FY 2025 · Dec 31, 2024 $191.26M
Stockholders Equity FY 2025 · Dec 31, 2023 $241.15M
Current Liabilities FY 2025 · Dec 31, 2025 $15.11M
Current Liabilities FY 2025 · Dec 31, 2024 $14.65M
Current Assets FY 2025 · Dec 31, 2025 $661.39M
Current Assets FY 2025 · Dec 31, 2024 $205.35M
Total Assets FY 2025 · Dec 31, 2025 $661.81M
Total Assets FY 2025 · Dec 31, 2024 $205.9M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.29
Eps Diluted FY 2025 · Dec 31, 2024 −$3.66
Eps Basic FY 2025 · Dec 31, 2025 −$2.29
Eps Basic FY 2025 · Dec 31, 2024 −$3.66
Sga Expense FY 2025 · Dec 31, 2025 $38.6M
Sga Expense FY 2025 · Dec 31, 2024 $23.82M
Rd Expense FY 2025 · Dec 31, 2025 $132.01M
Rd Expense FY 2025 · Dec 31, 2024 $168.58M
Net Income FY 2025 · Dec 31, 2025 −$154.65M
Net Income FY 2025 · Dec 31, 2024 −$177.81M
Operating Income FY 2025 · Dec 31, 2025 −$170.6M
Operating Income FY 2025 · Dec 31, 2024 −$192.4M